BUSINESS
Jupiter Life Line Hospitals IPO offers growth, market dominance. Should you subscribe?
Analysts are looking at the IPO favourably, given the projected CAGR of the hospital and its strong performance so far vis-à-vis its competitors
BUSINESS
Mid-day Mood | Indices hit day's low on crude surge; metals, PSU banks slump but pharma shines
Domestic benchmarks mirrored the weak trend seen across their global counterparts, with a surge in Brent crude prices acting as the major dampener.
BUSINESS
Sluggish demand, unclear debt reduction target push UPL into a pool of downgrades
While analysts and investors have moved away from UPL in anticipation of bleak prospects, the last two quarters of FY24 are expected to see improvement in demand for agrochemicals globally
BUSINESS
Mid-day Mood | Broader market shines even as blue-chips remain tepid
The Nifty Smallcap 100 and Nifty Midcap 100 indices have outperformed the benchmark Nifty 50 through the past month.
BUSINESS
Rollover of short positions hint at muted September F&O series for Nifty, broader indices offer some relief
The August series was marked by the liquidation of long positions by FIIs and a rise in rollovers in short bets to the September series. Analysts, however, say while the bears gained the upper hand as far as the Nifty50 is concerned, bulls were the winners in the broader market
BUSINESS
Mid-day Mood | Market extends early gains, strong Q1 GDP growth aids sentiment
Strong GDP growth in April-June quarter at 7.8 percent brightened India's growth outlook and prompted gains in today's session
BUSINESS
Why PE firms may find Cipla acquisition a different ball game
Cipla is already on top of the game, enjoys the best operational efficiencies, have a strong talent and management as well as robust portfolios, said one analyst. Scaling up specialty segments or diving deep into the biosimilars space will be the best options for PE firms, analysts suggested.
BUSINESS
Mid-day Mood | Indices scale day's high on upbeat global cues; all sectors in green
Domestic indices mirrored the upbeat trend across global markets after jobs data from the US hinted at a cooldown in the labour market which fanned expectations of a pause in rate hikes from the US Fed.
BUSINESS
Home and away: Indian pharma firms reap the best of both worlds in Q1 FY24
Improved pricing and competitive environment in the US and resilient sales in the domestic market aided an uptick in revenue. Easing raw material inflation and lower freight soothed margin pressure.
BUSINESS
Bullish on India: SRF poised to benefit from growing China+1 opportunities
SRF hopes to emerge as an alternative to China as a supplier of specialty chemicals. Its capacity expansion and dedication to fluorochemicals and specialty chemicals will drive its long-term growth.
BUSINESS
Mid-day Mood | Indices move in narrow range amid tepid buying; metals, realty shine
The lacklustre trade on August 28 mirrored a similar trend across global markets. US and most Asian markets are witnessed a similar trend as they posted minor gains.
BUSINESS
Mid-day Mood | Indices sustain early momentum; pharma, PSU banks lead the way
Benchmark indices opened on a positive note on August 28, tracking positive cues from Asian markets.
BUSINESS
China lines up a host of measures to ease market unrest, drive economic growth
Chinese authorities have rolled out a slew of measures in recent months to try and win back investors, bolster capital markets and fuel an increase in domestic spending.
BUSINESS
Biocon well-positioned to leverage opportunities from US drug patent expiries: CEO Siddharth Mittal
Biosimilars have led the growth in the April-June 2023 period and will continue to do so. The company also hopes to capitalise on its already strong presence in the US market, and stay ahead of the competition in the Indian market.
BUSINESS
Mid-day Mood | Market extends fall on Fed rate hike fears, inflation worries; most sectors in red
The Indian equity market mirrored the weak trend across global counterparts and opened lower on August 17.
BUSINESS
Cipla shares fall after FDA suspends license of Patalganga unit for 10 days
Cipla said that it wasn't in agreement with the FDA rulings and will appeal against the order to the state government.
BUSINESS
Street roots for Lupin but pricey valuations a spoiler for brokerages
Aside from expensive valuations, the Street remains bullish on the growth prospects for Lupin, especially after the approval of its blockbuster inhalation drug, the generic of Spiriva.
BUSINESS
Divi's Labs: China+1 sentiment to keep drugmaker on the path of API leadership
Emerging $20 billion generics opportunity, cost leadership, existing capacity, excellent regulatory track record, operational efficiency and laser-sharp focus on IP compliance can help the company win big, say analysts.
BUSINESS
F&O Manual | IT pulls up Nifty from day’s low, analysts expect consolidation to continue
If the Nifty slips below the crucial support of 19,300, it will witness further selling pressure towards lower levels
BUSINESS
Mid-day Mood | Rebound in IT stocks helps indices come off the day's low
A sharp sell-off across global markets on the back of Fitch's warnings to downgrade as many as 10 US banks weighed on the sentiment for domestic equities.
BUSINESS
Brokerages cautious on Divi's Labs, valuation a big worry
Divi's topline and bottomline came in well below the Street estimates, while operating profit margin improved on a sequential basis in the April-June quarter
BULLISH-ON-INDIA
Alkyl Amines: Changing dynamics in pharma API creates multiple growth triggers
The company’s capacity expansion plus the government’s push towards China plus on will put it on firm footing, towards revenue CAGR of 14%.
BUSINESS
Navin Fluorine: Plenty of growth levers to rule the long-term story
With robust earnings visibility thanks to its long-term contracts, a tilt in sales mix towards high-margin, high-value businesses, extensive capacity expansion-led growth, and resilient R&D infra, Navin Fluorine is on a superior growth trajectory.
BUSINESS
Mid-day Mood | Indices off the day's low; metals, PSU banks bleed with most sectors in red
Benchmark indices extended their losses to the third session, bogged down by weak cues from global markets.
